(Q34767394)

4 August 2017

1 reference

title

Who should receive HMG CoA reductase inhibitors? (English)

1 reference

4 August 2017

Koon K Teo

1

1 reference

4 August 2017

Jeffrey R Burton

series ordinal

2

1 reference

4 August 2017

publication date

1 January 2002

1 reference

4 August 2017

1 reference

4 August 2017

volume

62

1 reference

4 August 2017

issue

12

1 reference

4 August 2017

page(s)

1707-1715

1 reference

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

4 August 2017

cites work

1 reference

12 December 2020

Lipid-lowering therapy in low-risk patients

1 reference

12 December 2020

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

12 December 2020

Are statins anti-inflammatory? Issues in the design and conduct of the pravastatin inflammation C-reactive protein evaluation

1 reference

12 December 2020

Cholesterol and coronary heart disease. Future directions

1 reference

12 December 2020

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

12 December 2020

Statin trials and goals of cholesterol-lowering therapy

1 reference

12 December 2020

The care gap: improving delivery of patient care

1 reference

12 December 2020

Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction

1 reference

12 December 2020

Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease

1 reference

12 December 2020

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

1 reference

12 December 2020

HMG-CoA reductase inhibitors in the prevention of stroke

1 reference

12 December 2020

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

12 December 2020

Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Harvard Atherosclerosis Reversibility Project (HARP) Group

1 reference

12 December 2020

Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease

1 reference

12 December 2020

Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS])

1 reference

12 December 2020

Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.

1 reference

12 December 2020

Atherosclerosis. Potential targets for stabilization and regression

1 reference

12 December 2020

Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS)

1 reference

12 December 2020

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

12 December 2020

Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT).

1 reference

12 December 2020

Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials

1 reference

12 December 2020

Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project

1 reference

12 December 2020

Time Trends in the Use of Cholesterol-Lowering Agents in Older Adults

1 reference

12 December 2020

Antiatherothrombotic properties of statins: implications for cardiovascular event reduction

1 reference

12 December 2020

Rationale and design of the Cardiac Hospitalization Atherosclerosis Management Program at the University of California Los Angeles.

1 reference

12 December 2020

The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts

1 reference

12 December 2020

Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S)

1 reference

12 December 2020

Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

1 reference

12 December 2020

Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).

1 reference

12 December 2020

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

1 reference

12 December 2020

10.2165/00003495-200262120-00001

Identifiers

DOI

1 reference

Dimensions Publication ID

4 August 2017

1009356045

0 references

1 reference